title: The clinical use of PET/CT in the evaluation of melanoma.
abstract: Positron emission tomography combined with computed tomography (PET/CT) has emerged in the last decade as a dominant imaging modality used for staging, monitoring response and surveillance of various cancers, including melanoma. Using 2-deoxy-2-((18)F)fluoro-D-glucose ((18)F-FDG) as the radiopharmaceutical, PET/CT has demonstrated its efficacy and its utility in the management of patients with advanced melanoma. Nonetheless, challenges remain in the early stage evaluation of melanoma and in the development of novel radiotracers to better characterize lesions found on PET/CT. This chapter focuses on the advantages and limitations of this imaging modality in melanoma. We also detail and describe the approach to perform (18)F-FDG PET/CT, the methods to accurately quantify lesions, as well as the pearls/pitfalls of image interpretation. Finally, an overview of preclinical and investigational clinical radiopharmaceuticals is presented.
authors.affiliation: Département de Radiobiologie et de Médecine Nucléaire, Université de Sherbrooke, Sherbrooke, Québec, Canada.
authors.forename: Khun Visith
authors.initials: KV
authors.lastname: Keu
authors.forename: Andrei H
authors.initials: AH
authors.lastname: Iagaru
mesh_terms: D000818:Animals; D006801:Humans; D008545:Melanoma / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D011859:Radiography; D012878:Skin Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed